Better treatment and monitoring for Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new approach to treating Alzheimer's disease by improving both treatment and monitoring. It may help people with mild to moderate Alzheimer's who have specific brain changes seen on scans and in spinal fluid tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mild to moderate memory loss (score of 16-25 on a standard memory test)
- You have specific changes in your spinal fluid that suggest Alzheimer's disease
- An MRI scan shows brain shrinkage in areas linked to memory
- A PET scan shows changes in brain activity and amyloid plaques, which are signs of Alzheimer's
- You do not have active cancer, severe heart disease, or serious liver or kidney problems
- You do not have other brain diseases like Parkinson's, Lewy body dementia, or a history of stroke that might explain your symptoms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral diabetes medicine called semaglutide can help people with mild-to-moderate Alzheimer's disease. It may work by reducing inflammation or protecting brain cells, and researchers want to see if it slows memory loss.
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
This study tests if a combination of insulin and semaglutide (a diabetes drug) can improve memory and thinking in people with mild cognitive impairment (MCI) who also have metabolic syndrome (a cluster of health issues like large waist, high blood sugar, and high blood pressure). It aims to see if treating blood sugar problems helps protect the brain.
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
This trial tests if semaglutide, a diabetes and weight-loss medication, can improve psoriasis symptoms and reduce inflammation. It may be an option for people with both psoriasis and overweight or obesity, with or without diabetes.
This study looks at whether the oral medication semaglutide can help treat chronic kidney disease in people who have both type 2 diabetes and a fatty liver related to metabolism. It aims to see if the drug can improve kidney function and liver health.
Hear when a new Alzheimer Disease (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.